Development of a novel treatment for IBD by inhibition of topical JAK signaling in the intestin.

2023 Fiscal Year Research-status Report

• Project/Area Number: 23K07413
• Research Institution: Tokyo Medical and Dental University
• Principal Investigator: 藤井 俊光 東京医科歯科大学, 大学院医歯学総合研究科, 寄附講座准教授 (30547451)
• Co-Investigator(Kenkyū-buntansha): 永石 宇司 東京医科歯科大学, 大学院医歯学総合研究科, 寄附講座准教授 (60447464)
• Project Period (FY): 2023-04-01 – 2026-03-31
• Keywords: 炎症性腸疾患 / JAKシグナル / Drug Delivery System

Outline of Annual Research Achievements

JAK阻害薬はIBDにおいて高い寛解導入率を示し、生物学的製剤の不応例にも有効性が認められているにもかかわらず、感染症や血栓症など全身性の合併症が問題となり安易な導入は回避すべき位置づけとなっている。本研究で我々はこのJAK阻害薬を腸管局所へ直接デリバリーさせる坐剤や注腸製剤といった経直腸投与の局所製剤を開発することで、薬剤の全身への曝露を回避し合併症リスクを低減させつつ、直腸を含めた遠位大腸の炎症の鎮静化、それによる臨床的寛解、QOLの改善、粘膜治癒の達成による発癌抑制、また長期予後の改善をめざしている。そして当該期間に実施した研究結果から、以下のような成果が得られた。
１）JAK阻害薬の原末から、試験的な注腸剤を独自に調整することに成功した。２）次に正常マウスにおける毒性試験を行うにあたり、1回投与量や投与期間に関して多岐に亘るプロトコールを作成し、適切と思われるいくつかの条件を見出すことができた。３）そしてこれらのプロトコールを用いて野生型C57BL/6マウスにJAK阻害薬を注腸投与し、網羅的な病理学的解析を行った結果、血栓症や日和見感染、発癌性など想定された副反応を一切誘発しない最適な条件を見出すことに成功した。
これらの研究成果は、全身投与で想定されるようなJAK阻害薬の毒性は、その経直腸投与によって回避することが可能であることを示唆している。さらに現在、我々が見出した上記プロトコールに対して、より客観性を備えたデータを集積する目的で、single cell RNA seqによる網羅的解析を導入する準備を行っている。また、このプロトコールを用いたマウスIBDモデルにおける安全性試験や有効性試験の準備に着手しつつある。

Current Status of Research Progress

2: Research has progressed on the whole more than it was originally planned.

Reason

IBDの病態に対しJAK阻害剤は有効性が確認されている一方、その重篤な副反応が大きな課題であり、Drug Delivery　Systemの工夫によって難治例に対する安全で有効な新規治療薬が開発できる可能性に着目しているが、今回我々は独自のJAK阻害注腸剤を調整し、その適切な投与条件を見出し、そして想定された副反応を全て回避できる条件を確立できたことは大きな成果であるといえる。

Strategy for Future Research Activity

次年度は我々が独自に調整したJAK阻害注腸剤とその投与プロトコールを用いて、これによる副反応の有無をさらに詳細に解析するために、single cell RNA seqによる網羅的解析を導入し各臓器・各細胞腫に与える影響を解析する予定である。また同プロトコールの安全性や有効性を客観的に評価するために、動物IBDモデルを誘発しその臨床および病理学的解析、フローサイトメトリー、サイトカイン測定、また免疫組織染色などを行う予定である。

Causes of Carryover

理由：試薬等が計画当初より廉価で購入可能であったため。
使用計画：　検討する数・種類を拡大して解析を行うため、試薬を増量して購入する予定である。

Research Products

• [Journal Article] Single cell analysis revealed that two distinct, unique CD4+ T cell subsets were increased in the small intestinal intraepithelial lymphocytes of aged mice. (2024)
  • Author(s): Yuki Yonemoto, Yasuhiro Nemoto, Ryo Morikawa, Nana Shibayama, Shigeru Oshima, Takashi Nagaishi, Tomohiro Mizutani, Go Ito, Satoru Fujii, Ryuichi Okamoto.
  • Journal Title: Frontiers in Immunology. Volume: 15 Pages: e1340048
  • DOI: 10.3389/fimmu.2024.1340048.
  • Peer Reviewed
• [Journal Article] IgA による腸内細菌叢調節と腸管粘膜防御の検証. (2023)
  • Author(s): 永石宇司.
  • Journal Title: 東京医科歯科大学医科同窓会会報. Volume: 301 Pages: 23
• [Journal Article] 炎症性腸疾患モデルにおける炎症性発癌機構の解析. (2023)
  • Author(s): 井上忠彦, 永石宇司.
  • Journal Title: 細胞. Volume: 55 Pages: 1005-1009
• [Journal Article] IgAによる回腸免疫恒常性の維持. (2023)
  • Author(s): 永石宇司, 井上忠彦, 伏見萌音, 山田大貴, 岡本隆一, 安達貴弘.
  • Journal Title: 消化器病学サイエンス. Volume: 7 Pages: 86-89
• [Journal Article] 慢性下痢の原因となる薬剤. (2023)
  • Author(s): 山田大貴, 永石宇司.
  • Journal Title: IBD Research. Volume: 17 Pages: 112-115
• [Journal Article] A case of venous stasis colitis possibly caused by eplerenone (2023)
  • Author(s): Saito E, Ohtsuka K, Kawamoto A, Fujii T, Takenaka K, Hibiya S, Shimizu H, Nagahori M, Tomii S, Okamoto R
  • Journal Title: Clin J Gastroenterol Volume: 16 Pages: 69-72
  • DOI: 10.1007/s12328-022-01722-5
  • Peer Reviewed
• [Journal Article] Transmural remission characterized by high biologic concentrations demonstrates better prognosis in Crohn's disease (2023)
  • Author(s): Takenaka K, Kawamoto A, Kitazume Y, Fujii T, Udagawa Y, Shimizu H, Hibiya S, Nagahori M, Ohtsuka K, Watanabe M, Okamoto R
  • Journal Title: J Crohns Colitis Volume: 17 Pages: 855-862
  • DOI: 10.1093/ecco-jcc/jjac185
  • Peer Reviewed
• [Journal Article] Serum Leucine-Rich α2 Glycoprotein: A Novel Biomarker for Transmural Inflammation in Crohn's Disease (2023)
  • Author(s): Takenaka K, Kitazume Y, Kawamoto A, Fujii T, Udagawa Y, Wanatabe R, Shimizu H, Hibiya S, Nagahori M, Ohtsuka K, Sato H, Hirakawa A, Watanabe M, Okamoto R
  • Journal Title: Am J Gastroenterol Volume: 118 Pages: 1028-1035
  • DOI: 10.14309/ajg.0000000000002127
  • Peer Reviewed
• [Journal Article] Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study (2023)
  • Author(s): Matsuoka K, Yamazaki H, Nagahori M, Kobayashi T, Omori T, Mikami Y, Fujii T, Shinzaki S, Saruta M, Matsuura M, Yamamoto T, Motoya S, Hibi T, Watanabe M, Fernandez J, Fukuhara S, Hisamatsu T
  • Journal Title: J Gastroenterol Volume: 58 Pages: 751-765
  • DOI: 10.1007/s00535-023-02005-7
  • Peer Reviewed
• [Journal Article] Diagnosis and Clinical Features of Perianal Lesions in Newly Diagnosed Crohn's Disease: Subgroup Analysis from Inception Cohort Registry Study of Patients with Crohn's Disease (iCREST-CD) (2023)
  • Author(s): Yamamoto T, Nakase H, Watanabe K, Shinzaki S, Takatsu N, Fujii T, Okamoto R, Matsuoka K, Yamada A, Kunisaki R, Matsuura M, Shiga H, Bamba S, Mikami Y, Shimoyama T, Motoya S, Torisu T, Kobayashi T, Ohmiya N, Saruta M, Matsuda K, Matsumoto T, Maemoto A, Murata Y, Yoshigoe S, Nagasaka S, Yajima T, Hisamatsu T
  • Journal Title: J Crohns Colitis Volume: 17 Pages: 1193-1206
  • DOI: 10.1093/ecco-jcc/jjad038
  • Peer Reviewed
• [Journal Article] Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies (2023)
  • Author(s): Gao X, Fujii T, Ye B D, Chou J W, Sugimoto K, Cao Q, Kligys K, Murakoshi K, Teng D, Zhang Y, Nakase H
  • Journal Title: J Gastroenterol Hepatol Volume: Online ahead of print Pages: ahead of print
  • DOI: 10.1111/jgh.16358
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] aintenance Risankizumab Sustains Induction Response in Patients with Crohn’s Disease in a Randomized Phase 3 Trial (2023)
  • Author(s): Ferrante M, Irving P M, Abreu M T, Axler J, Gao X, Cao Q, Fujii T, Rausch A, Torres J, Neimark E, Song A, Wallace K, Kligys K, Berg S, Liao X, Zhou Q, Kalabic J, Feagan B, Panaccione R
  • Journal Title: J Crohns Colitis Volume: Online ahead of print Pages: ahead of print
  • DOI: 10.1093/ecco-jcc/jjad168
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] Combination of leucine-rich alpha-2 glycoprotein and fecal markers detect Crohn’s disease activity confirmed by balloon-assisted enteroscopy (2023)
  • Author(s): 8．Ami Kawamoto, Kento Takenaka, Shuji Hibiya, Yoshio Kitazume, Hiromichi Shimizu, Toshimitsu Fujii, Eiko Saito, Kazuo Ohtsuka, Ryuichi Okamoto
  • Journal Title: Intest Res Volume: Epub ahead of print Pages: ahead of print
  • DOI: 10.5217/ir.2023.00092
  • Peer Reviewed / Open Access
• [Journal Article] COVID-19 severity is associated with the risk of gastrointestinal bleeding (2023)
  • Author(s): Shuji Hibiya, Takashi Fujii, Toshimitsu Fujii, Shinji Suzuki, Mayumi Kondo, Shinya Ooka, Y Furumoto, S Azuma, K Tanaka, H Kurata, S Tanaka, M Kurosaki, K Nagayama, F Kusano, Y Iizuka, T Kawamura, H Ikemiyagi, S Sakita,T Yauchi, H Watanabe, A Kawamoto, Y Matsuyama, K Ohtsuka, R Okamoto
  • Journal Title: BMJ Open Gastroenterol Volume: 10 Pages: e001199
  • DOI: 10.1136/bmjgast-2023-001199
  • Peer Reviewed / Open Access
• [Journal Article] 【炎症性腸疾患に対する検査法の進歩】Cross-sectional imagingとしてのMRIとtransmural healing (2023)
  • Author(s): 1.藤井 俊光, 岡本 隆一
  • Journal Title: 日本消化器病学会雑誌 Volume: 120 Pages: 888-897
  • Peer Reviewed
• [Journal Article] 【小腸画像診断のトピックス】MR enterography (2023)
  • Author(s): 2.竹中 健人, 藤井 俊光, 大塚 和朗, 岡本 隆一
  • Journal Title: 胃と腸 Volume: 58 Pages: 1491-1498
  • Peer Reviewed
• [Journal Article] 【潰瘍性大腸炎に対する同種同効薬を使い分ける!】JAK阻害薬はすべて同じ使い方か? (2023)
  • Author(s): 3.藤井 俊光
  • Journal Title: IBD Research Volume: 17 Pages: 267-274
• [Presentation] A pathogenic role of activated mucosal-associated invariant T cells in an animal model of Inflammatory Bowel Disease. (2024)
  • Author(s): Yusuke Yasutomi, Asako Chiba, Keiichi Haga, Goh Murayama, Ayako Makiyama, Akihito Nagahara, Takashi Nagaishi, Sachiko Miyake.
  • Organizer: Annual meeting of European Crohn's and Colitis Organisation 2024.
  • Int'l Joint Research
• [Presentation] Downregulated apelin expression in T cells in the setting of chronic colitis. (2024)
  • Author(s): Tadahiko Inoue, Mone Fushimi, Daiki Yamada, Taro Watabe, Mamoru Watanabe, Ryuichi Okamoto, Takashi Nagaishi.
  • Organizer: Annual meeting of European Crohn's and Colitis Organisation 2024.
  • Int'l Joint Research
• [Presentation] B cell receptor signaling-mediated activation in lymphoid tissues is regulated by the long isoform of CEACAM1. (2024)
  • Author(s): Tadahiko Inoue, Mone Fushimi, Naoya Tsugawa, Daiki Yamada, Taro Watabe, Mamoru Watanabe, Ryuichi Okamoto, Takahiro Adachi, Richard S. Blumberg, Takashi Nagaishi.
  • Organizer: Annual meeting of Japanese Society of Immunology 2024.
  • Int'l Joint Research
• [Presentation] APL downregulation in T cells in an animal model of chronic colitis. (2024)
  • Author(s): Mone Fushimi, Tadahiko Inoue, Daiki Yamada, Taro Watabe, Mamoru Watanabe, Ryuichi Okamoto, Takashi Nagaishi.
  • Organizer: Annual meeting of Japanese Society of Immunology 2024.
  • Int'l Joint Research
• [Presentation] 難治性潰瘍性大腸炎におけるカロテグラストとbiologicsのdual therapy (2024)
  • Author(s): 藤井 俊光, 日比谷 秀爾, 河本 亜美, 田村 皓子, 森川 亮, 小林 桜子, 清水 寛路, 齊藤 詠子, 竹中 健人, 大塚 和朗, 岡本 隆一
  • Organizer: 第20回日本消化管学会総会学術集会
• [Presentation] Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a final report of effectiveness and safety data (2024)
  • Author(s): Katsuyoshi Matsuoka, Satoshi Motoya, Takayuki Yamamoto, Minoru Matsuura, Toshimitsu Fujii, Shinichiro Shinzaki, Yohei Mikami, Shoko Arai, Junichi Oshima, Yutaka Endo, Hirotoshi Yuasa, Masato Hoshi, Keiko Sato, Tadakazu Hisamatsu
  • Organizer: 19th Congress of ECCO
  • Int'l Joint Research
• [Presentation] Clinical features and surgical necessity rate of fistulisingperianal disease in newly diagnosed patients with Crohn's disease: Interim analysis of inception cohort registry study of patients with Crohn's disease (iCREST-CD) (2024)
  • Author(s): N.Takatsu, T.Yamamoto, H.Nakase, S.Shinzaki, K.Watanabe, T.Fujii, R.Okamoto, K.Matsuoka, A.Yamada, R.Kunisaki, M.Matsuura, H.Shiga, S.Bamba, Y.Mikami, T.Shimoyama, S.Motoya, T.Torisu, T.Kobayashi, N.Ohmiya, M.Saruta, S.Yoshigoe, Y.Murata, T.Hisamatsu
  • Organizer: 19th Congress of ECCO
  • Int'l Joint Research
• [Presentation] Ozanimod as a once-daily oral therapy for Japanese patients with ulcerative colitis: results from the induction period of a phase 2/3 study (J-True North) (2024)
  • Author(s): Katsuyoshi Matsuoka, Hiroshi Nakase, Toshimitsu Fujii, Tadakazu Hisamatsu, Yasuo Suzuki, Mamoru Watanabe, Yoko Uchikawa, Shoichiro Goto, Go Fujimoto, Changliang Zhang, Toshifumi Hibi
  • Organizer: 19th Congress of ECCO
  • Int'l Joint Research
• [Presentation] APL downregulation in T cells in the setting of chronic colitis. (2023)
  • Author(s): Mone Fushimi, Tadahiko Inoue, Daiki Yamada, Taro Watabe, Mamoru Watanabe, Ryuichi Okamoto, Takashi Nagaishi.
  • Organizer: United European Gastroenterology Week 2024.
  • Int'l Joint Research
• [Presentation] 潰瘍性大腸炎におけるウパダシチニブ 30mg 及び 15mg 維持療法のベネフィット比較:第 III 相 U-ACHIEVE 試験 (2023)
  • Author(s): 藤井 俊光，佐藤 真弘，池田 公俊，仲瀬 裕志
  • Organizer: 第109回日本消化器病学会総会
• [Presentation] Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn's disease treated with upadacitinib (2023)
  • Author(s): M.C. Dubinsky, G. D’Haens, O. Dewit, P. Juillerat, R. Panaccione, T. Fujii, A.P. Lacerda, E. Dubcenco, S. Anyanwu, C. Doshi, M. Mallick, A. Garrison, J. Liu, E.V. Loftus Jr
  • Organizer: 18th Congress of ECCO
  • Int'l Joint Research
• [Presentation] Severe COVID-19 is associated with risk of lower gastrointestinal bleeding (2023)
  • Author(s): Shuij Hibiya, Takashi Fujii, Toshimitsu Fujii, Kazuo Ohtsuka, Ryuichi Okamoto
  • Organizer: UEG Week 2023 欧州消化器病学会
  • Int'l Joint Research
• [Presentation] COMBINING LEUCINE-RICH ALPHA-2 GLYCOPROTEIN AND FAECAL BIOMARKERS FOR ACCURATE MONITORING OF SMALL BOWEL ACTIVITY IN CROHN’S DISEASE (2023)
  • Author(s): A. Kawamoto, K. Takenaka, S. Hibiya, Y. Kitazume, K. Ito, H. Shimizu, T. Fujii, E. Saito, K. Ohtsuka, R. Okamoto
  • Organizer: UEG Week 2023 欧州消化器病学会
  • Int'l Joint Research
• [Presentation] DUAL THERAPY WITH CAROTEGRAST (AJM300: ORAL α4 INTEGRIN ANTAGONIST) AND BIOLOGICS FOR REFRACTORY ULCERATIVE COLITIS (2023)
  • Author(s): T. Fujii , S. Hibiya , H. Shimizu , A. Kawamoto , K. Takenaka , E. Saito , M. Nagahori , K. Ohtsuka , R. Okamoto
  • Organizer: UEG Week 2023 欧州消化器病学会
  • Int'l Joint Research
• [Presentation] Efficacy of Induction Upadacitinib Therapy in East Asian Patients With Moderately to Severely Active Crohn’s Disease (2023)
  • Author(s): Minhu Chen, Xiang Gao, Kenji Watanabe, Toshimitsu Fujii, Jae Hee Cheon, Shu-Chen Wei, Dennis Teng, Ana P Lacerda, Valencia P Remple, Hiroshi Nakase
  • Organizer: UEG Week 2023 欧州消化器病学会
  • Int'l Joint Research
• [Presentation] The Efficacy of Induction Treatment With Guselkumab in Patients with Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Induction Study Results at Week 12 by Prior Advanced Therapy History (2023)
  • Author(s): B. Bressler, L. Peyrin-Biroulet, J.R. Allegretti, K.G. Huang, M. Germinaro, N. Shipitofsky, Y. Miao, H. Zhang, M. Bortlik, T. Hlavaty, T. Fujii, B.G. Feagan, B.E. Sands, A. Dignass on behalf of the QUASAR Investigators
  • Organizer: UEG Week 2023 欧州消化器病学会
  • Int'l Joint Research
• [Presentation] Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib (2023)
  • Author(s): Marla C. Dubinsky, Geert D’Haens, Olivier Dewit, Pascal Juillerat, Remo Panaccione, Toshimitsu Fujii, Ana P Lacerda, Elena Dubcenco, Samuel Anyanwu, Chirag Doshi, Madhuja Mallick, Andrew Garrison, John Liu, Lena Thin, Edward V Loftus Jr
  • Organizer: AGW 2023
  • Int'l Joint Research
• [Presentation] Corticosteroid Discontinuation and Clinical Outcomes in Patients With Moderately to Severely Active Crohn’s Disease Treated With Upadacitinib (2023)
  • Author(s): Marla C. Dubinsky, Geert D’Haens, Olivier Dewit, Pascal Juillerat, Remo Panaccione, Toshimitsu Fujii, Ana P. Lacerda, Elena Dubcenco, Samuel Anyanwu, Chirag Doshi, Madhuja Mallick, Andrew Garrison, John Liu, Edward V. Loftus Jr
  • Organizer: DDW2023 米国消化器病学会
  • Int'l Joint Research
• [Presentation] Patients with Moderate-to-Severe Crohn’s Disease with and without Prior Biologic Failure Demonstrate Improved Endoscopic Outcomes with Risankizumab: Results from Phase 3 Induction and Maintenance Trials (2023)
  • Author(s): Marc Ferrante, Qian Cao, Toshimitsu Fujii, Astrid Rausch, Ezequiel Neimark, Alexandra Song, Kori Wallace, Kristina Kligys, Qing Zhou, Jasmina Kalabic, Brian Feagan
  • Organizer: DDW2023 米国消化器病学会
  • Int'l Joint Research
• [Presentation] Corticosteroid-Sparing Effect of Upadacitinib in Patients With Moderately to Severely Active Crohn’s Disease (2023)
  • Author(s): Marla C. Dubinsky, Geert D’Haens, Olivier Dewit, Pascal Juillerat, Remo Panaccione, Toshimitsu Fujii, Ana P Lacerda, Elena Dubcenco, Samuel Anyanwu, Chirag Doshi, John Liu, Andrew Garrison, Edward V Loftus Jr
  • Organizer: ACG 2023 - American College of Gastroenterology
  • Int'l Joint Research
• [Presentation] The Efficacy of Induction Treatment With Guselkumab in Patients with Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Induction Study Results at Week 12 by Prior Advanced Therapy History (2023)
  • Author(s): B. Bressler, L. Peyrin-Biroulet, J.R. Allegretti, K.G. Huang, M. Germinaro, N. Shipitofsky, Y. Miao, H. Zhang, M. Bortlik, T. Hlavaty, T. Fujii, B.G. Feagan, B.E. Sands, A. Dignass on behalf of the QUASAR Investigators
  • Organizer: ACG 2023 - American College of Gastroenterology
  • Int'l Joint Research
• [Presentation] Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib (2023)
  • Author(s): Marla C. Dubinsky, Geert D’Haens, Olivier Dewit, Pascal Juillerat, Remo Panaccione, Toshimitsu Fujii, Ana P Lacerda, Elena Dubcenco, Samuel Anyanwu, Chirag Doshi, Madhuja Mallick, Andrew Garrison, John Liu, Edward V Loftus Jr
  • Organizer: SGG Swiss congress 2023
  • Int'l Joint Research
• [Presentation] 難治性潰瘍性大腸炎に対するcarotegrastおよびbiologicsのdual therapyの検討 (2023)
  • Author(s): 藤井俊光、青沼優子、清水寛路、日比谷秀爾、河本亜美、齊藤詠子、竹中健人、長堀正和、大塚和朗、岡本隆一
  • Organizer: JDDW2023 日本消化器関連学会週間
• [Presentation] クローン病患者における過去に無効であった生物学的製剤数別のリサンキズマブの有効性 (2023)
  • Author(s): 藤井 俊光、佐藤 真弘、大野 浩太、久松 理一
  • Organizer: JDDW2023 日本消化器関連学会週間
• [Presentation] 炎症性腸疾患における両立支援の実際と課題 (2023)
  • Author(s): 藤井俊光
  • Organizer: JDDW2023 日本消化器関連学会週間
• [Presentation] 経口α4インテグリン阻害剤のポジショニングと期待 (2023)
  • Author(s): 藤井俊光
  • Organizer: JDDW2023 日本消化器関連学会週間
• [Presentation] クローン病肛門病変の生物学的製剤に対する内視鏡評価 (2023)
  • Author(s): 竹中健人、河本亜美、藤井俊光、日比谷秀爾、田村皓子、森川亮、小林桜子、清水寛路、齊藤詠子、長堀正和、大塚和朗、岡本隆一
  • Organizer: 第14回日本炎症性腸疾患学会学術集会
• [Presentation] 潰瘍性大腸炎に対するカロテグラストのリアルワールドとbiologicsとのdual therapy (2023)
  • Author(s): 藤井俊光、日比谷秀爾、河本亜美、田村皓子、森川亮、小林桜子、清水寛路、齊藤詠子、竹中健人、大塚和朗、岡本隆一
  • Organizer: 第14回日本炎症性腸疾患学会学術集会
• [Presentation] 難治性潰瘍性大腸炎におけるupadacitinib投与に伴う尋常性ざ瘡の解析 (2023)
  • Author(s): 藤井俊光、田村皓子、河本亜美、森川亮、小林桜子、日比谷秀爾、清水寛路、齊藤詠子、竹中健人、大塚和朗、岡本隆一
  • Organizer: 第14回日本炎症性腸疾患学会学術集会
• [Presentation] ウパダシチニブを投与した中等症から重症の活動性クローン病患者での副腎皮質ステロイドの中止と転帰 (2023)
  • Author(s): 藤井 俊光、幡井 裕乙、新山 勇人、仲瀬 裕志
  • Organizer: 第14回日本炎症性腸疾患学会学術集会
• [Presentation] IBD Advanced Therapyのstudyを紐解く (2023)
  • Author(s): 藤井俊光
  • Organizer: 第14回日本炎症性腸疾患学会学術集会